
Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
---|---|---|---|---|---|
NVST
Envista Holdings
|
$640.2M | $0.23 | 0.62% | 46.34% | $19.63 |
ALGN
Align Technology
|
$1.1B | $2.57 | 2.9% | 100.44% | $233.81 |
BIOLQ
Biolase
|
$13.5M | -$0.01 | 3.78% | -99.71% | $1.2000 |
MLSS
Milestone Scientific
|
$2.6M | -$0.01 | 40.26% | -50% | $2.13 |
SOLV
Solventum
|
$2.1B | $1.45 | 1.89% | 185.16% | $85.04 |
XRAY
Dentsply Sirona
|
$931.5M | $0.50 | -5.4% | 234.18% | $18.18 |
Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
---|---|---|---|---|---|---|---|
NVST
Envista Holdings
|
$19.72 | $19.63 | $3.3B | -- | $0.00 | 0% | 1.36x |
ALGN
Align Technology
|
$190.24 | $233.81 | $13.8B | 34.65x | $0.00 | 0% | 3.56x |
BIOLQ
Biolase
|
$0.0091 | $1.2000 | $333K | -- | $0.00 | 0% | 0.00x |
MLSS
Milestone Scientific
|
$0.62 | $2.13 | $48.5M | -- | $0.00 | 0% | 5.75x |
SOLV
Solventum
|
$73.03 | $85.04 | $12.6B | 33.81x | $0.00 | 0% | 1.53x |
XRAY
Dentsply Sirona
|
$15.81 | $18.18 | $3.2B | -- | $0.16 | 4.05% | 0.86x |
Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
---|---|---|---|---|
NVST
Envista Holdings
|
31.74% | 2.114 | 47.7% | 1.68x |
ALGN
Align Technology
|
-- | 2.280 | -- | 0.99x |
BIOLQ
Biolase
|
142.17% | -3.027 | 714.45% | 0.23x |
MLSS
Milestone Scientific
|
-- | 1.027 | -- | 0.62x |
SOLV
Solventum
|
70.81% | 1.088 | 60.15% | 0.64x |
XRAY
Dentsply Sirona
|
53.74% | 1.179 | 78.42% | 0.56x |
Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
---|---|---|---|---|---|---|
NVST
Envista Holdings
|
$336M | $47.4M | -24.02% | -34.78% | 6.21% | -$5.6M |
ALGN
Align Technology
|
$680.1M | $135.3M | 10.72% | 10.72% | 13.81% | $27.4M |
BIOLQ
Biolase
|
$4.4M | -$695K | -129.74% | -21668.17% | -7.48% | -$4.5M |
MLSS
Milestone Scientific
|
$1.6M | -$2M | -79.98% | -79.98% | -89.49% | -$1M |
SOLV
Solventum
|
$1.1B | $152M | 3.34% | 11.75% | 6.86% | -$80M |
XRAY
Dentsply Sirona
|
$466M | $70M | -19.2% | -35.57% | 7.17% | -$12M |
Align Technology has a net margin of 2.92% compared to Envista Holdings's net margin of 9.52%. Envista Holdings's return on equity of -34.78% beat Align Technology's return on equity of 10.72%.
Company | Gross Margin | Earnings Per Share | Invested Capital |
---|---|---|---|
NVST
Envista Holdings
|
54.47% | $0.10 | $4.4B |
ALGN
Align Technology
|
69.45% | $1.27 | $3.8B |
Envista Holdings has a consensus price target of $19.63, signalling downside risk potential of -0.48%. On the other hand Align Technology has an analysts' consensus of $233.81 which suggests that it could grow by 22.9%. Given that Align Technology has higher upside potential than Envista Holdings, analysts believe Align Technology is more attractive than Envista Holdings.
Company | Buy Ratings | Hold Ratings | Sell Ratings |
---|---|---|---|
NVST
Envista Holdings
|
4 | 9 | 1 |
ALGN
Align Technology
|
9 | 5 | 0 |
Envista Holdings has a beta of 1.004, which suggesting that the stock is 0.421% more volatile than S&P 500. In comparison Align Technology has a beta of 1.633, suggesting its more volatile than the S&P 500 by 63.291%.
Envista Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Align Technology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Envista Holdings pays -- of its earnings as a dividend. Align Technology pays out -- of its earnings as a dividend.
Envista Holdings quarterly revenues are $616.9M, which are smaller than Align Technology quarterly revenues of $979.3M. Envista Holdings's net income of $18M is lower than Align Technology's net income of $93.2M. Notably, Envista Holdings's price-to-earnings ratio is -- while Align Technology's PE ratio is 34.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Envista Holdings is 1.36x versus 3.56x for Align Technology. Usually stocks with elevated PS ratios are considered overvalued.
Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
---|---|---|---|---|
NVST
Envista Holdings
|
1.36x | -- | $616.9M | $18M |
ALGN
Align Technology
|
3.56x | 34.65x | $979.3M | $93.2M |
Biolase has a net margin of 2.92% compared to Envista Holdings's net margin of -13.16%. Envista Holdings's return on equity of -34.78% beat Biolase's return on equity of -21668.17%.
Company | Gross Margin | Earnings Per Share | Invested Capital |
---|---|---|---|
NVST
Envista Holdings
|
54.47% | $0.10 | $4.4B |
BIOLQ
Biolase
|
40.39% | -$0.04 | $12.4M |
Envista Holdings has a consensus price target of $19.63, signalling downside risk potential of -0.48%. On the other hand Biolase has an analysts' consensus of $1.2000 which suggests that it could grow by 21878.02%. Given that Biolase has higher upside potential than Envista Holdings, analysts believe Biolase is more attractive than Envista Holdings.
Company | Buy Ratings | Hold Ratings | Sell Ratings |
---|---|---|---|
NVST
Envista Holdings
|
4 | 9 | 1 |
BIOLQ
Biolase
|
1 | 1 | 0 |
Envista Holdings has a beta of 1.004, which suggesting that the stock is 0.421% more volatile than S&P 500. In comparison Biolase has a beta of 0.028, suggesting its less volatile than the S&P 500 by 97.213%.
Envista Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biolase offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Envista Holdings pays -- of its earnings as a dividend. Biolase pays out -- of its earnings as a dividend.
Envista Holdings quarterly revenues are $616.9M, which are larger than Biolase quarterly revenues of $10.9M. Envista Holdings's net income of $18M is higher than Biolase's net income of -$1.4M. Notably, Envista Holdings's price-to-earnings ratio is -- while Biolase's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Envista Holdings is 1.36x versus 0.00x for Biolase. Usually stocks with elevated PS ratios are considered overvalued.
Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
---|---|---|---|---|
NVST
Envista Holdings
|
1.36x | -- | $616.9M | $18M |
BIOLQ
Biolase
|
0.00x | -- | $10.9M | -$1.4M |
Milestone Scientific has a net margin of 2.92% compared to Envista Holdings's net margin of -89.35%. Envista Holdings's return on equity of -34.78% beat Milestone Scientific's return on equity of -79.98%.
Company | Gross Margin | Earnings Per Share | Invested Capital |
---|---|---|---|
NVST
Envista Holdings
|
54.47% | $0.10 | $4.4B |
MLSS
Milestone Scientific
|
73.8% | -$0.02 | $4.5M |
Envista Holdings has a consensus price target of $19.63, signalling downside risk potential of -0.48%. On the other hand Milestone Scientific has an analysts' consensus of $2.13 which suggests that it could grow by 243.96%. Given that Milestone Scientific has higher upside potential than Envista Holdings, analysts believe Milestone Scientific is more attractive than Envista Holdings.
Company | Buy Ratings | Hold Ratings | Sell Ratings |
---|---|---|---|
NVST
Envista Holdings
|
4 | 9 | 1 |
MLSS
Milestone Scientific
|
1 | 0 | 0 |
Envista Holdings has a beta of 1.004, which suggesting that the stock is 0.421% more volatile than S&P 500. In comparison Milestone Scientific has a beta of 0.801, suggesting its less volatile than the S&P 500 by 19.924%.
Envista Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Milestone Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Envista Holdings pays -- of its earnings as a dividend. Milestone Scientific pays out -- of its earnings as a dividend.
Envista Holdings quarterly revenues are $616.9M, which are larger than Milestone Scientific quarterly revenues of $2.2M. Envista Holdings's net income of $18M is higher than Milestone Scientific's net income of -$2M. Notably, Envista Holdings's price-to-earnings ratio is -- while Milestone Scientific's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Envista Holdings is 1.36x versus 5.75x for Milestone Scientific. Usually stocks with elevated PS ratios are considered overvalued.
Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
---|---|---|---|---|
NVST
Envista Holdings
|
1.36x | -- | $616.9M | $18M |
MLSS
Milestone Scientific
|
5.75x | -- | $2.2M | -$2M |
Solventum has a net margin of 2.92% compared to Envista Holdings's net margin of 6.62%. Envista Holdings's return on equity of -34.78% beat Solventum's return on equity of 11.75%.
Company | Gross Margin | Earnings Per Share | Invested Capital |
---|---|---|---|
NVST
Envista Holdings
|
54.47% | $0.10 | $4.4B |
SOLV
Solventum
|
53.82% | $0.78 | $11.2B |
Envista Holdings has a consensus price target of $19.63, signalling downside risk potential of -0.48%. On the other hand Solventum has an analysts' consensus of $85.04 which suggests that it could grow by 16.45%. Given that Solventum has higher upside potential than Envista Holdings, analysts believe Solventum is more attractive than Envista Holdings.
Company | Buy Ratings | Hold Ratings | Sell Ratings |
---|---|---|---|
NVST
Envista Holdings
|
4 | 9 | 1 |
SOLV
Solventum
|
2 | 6 | 0 |
Envista Holdings has a beta of 1.004, which suggesting that the stock is 0.421% more volatile than S&P 500. In comparison Solventum has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
Envista Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Solventum offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Envista Holdings pays -- of its earnings as a dividend. Solventum pays out -- of its earnings as a dividend.
Envista Holdings quarterly revenues are $616.9M, which are smaller than Solventum quarterly revenues of $2.1B. Envista Holdings's net income of $18M is lower than Solventum's net income of $137M. Notably, Envista Holdings's price-to-earnings ratio is -- while Solventum's PE ratio is 33.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Envista Holdings is 1.36x versus 1.53x for Solventum. Usually stocks with elevated PS ratios are considered overvalued.
Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
---|---|---|---|---|
NVST
Envista Holdings
|
1.36x | -- | $616.9M | $18M |
SOLV
Solventum
|
1.53x | 33.81x | $2.1B | $137M |
Dentsply Sirona has a net margin of 2.92% compared to Envista Holdings's net margin of 2.28%. Envista Holdings's return on equity of -34.78% beat Dentsply Sirona's return on equity of -35.57%.
Company | Gross Margin | Earnings Per Share | Invested Capital |
---|---|---|---|
NVST
Envista Holdings
|
54.47% | $0.10 | $4.4B |
XRAY
Dentsply Sirona
|
53.02% | $0.10 | $4.3B |
Envista Holdings has a consensus price target of $19.63, signalling downside risk potential of -0.48%. On the other hand Dentsply Sirona has an analysts' consensus of $18.18 which suggests that it could grow by 14.98%. Given that Dentsply Sirona has higher upside potential than Envista Holdings, analysts believe Dentsply Sirona is more attractive than Envista Holdings.
Company | Buy Ratings | Hold Ratings | Sell Ratings |
---|---|---|---|
NVST
Envista Holdings
|
4 | 9 | 1 |
XRAY
Dentsply Sirona
|
2 | 13 | 0 |
Envista Holdings has a beta of 1.004, which suggesting that the stock is 0.421% more volatile than S&P 500. In comparison Dentsply Sirona has a beta of 0.944, suggesting its less volatile than the S&P 500 by 5.559%.
Envista Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Dentsply Sirona offers a yield of 4.05% to investors and pays a quarterly dividend of $0.16 per share. Envista Holdings pays -- of its earnings as a dividend. Dentsply Sirona pays out -13.85% of its earnings as a dividend.
Envista Holdings quarterly revenues are $616.9M, which are smaller than Dentsply Sirona quarterly revenues of $879M. Envista Holdings's net income of $18M is lower than Dentsply Sirona's net income of $20M. Notably, Envista Holdings's price-to-earnings ratio is -- while Dentsply Sirona's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Envista Holdings is 1.36x versus 0.86x for Dentsply Sirona. Usually stocks with elevated PS ratios are considered overvalued.
Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
---|---|---|---|---|
NVST
Envista Holdings
|
1.36x | -- | $616.9M | $18M |
XRAY
Dentsply Sirona
|
0.86x | -- | $879M | $20M |
Signup to receive the latest stock alerts
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Market Cap: $4.2T
P/E Ratio: 58x
Market Cap: $3.8T
P/E Ratio: 43x
Market Cap: $3.1T
P/E Ratio: 35x
SharpLink Gaming [SBET] is down 2.6% over the past day.
Exodus Movement [EXOD] is down 4.14% over the past day.
Unity Software [U] is up 7.51% over the past day.